Is CDXS or SGMO more profitable?

Codexis has a net margin of -40.97% compared to Sangamo Therapeutics' net margin of -310.81%. Codexis' return on equity of -68.09% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -40.97% -68.09% -23.72% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Is AGEN or SGMO more profitable?

Agenus has a net margin of 50.49% compared to Sangamo Therapeutics' net margin of -310.81%. Agenus' return on equity of -31.66% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Do analysts recommend SGMO or DOMH?

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 3,135.29%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SGMO or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Dominari -31.37% -206.20% -155.26%

Sangamo Therapeutics (SGMO) Competitors

$0.17 +0.01 (+3.03%)

As of 03:58 PM Eastern

Compare

SGMO vs. SABS, CDXS, AGEN, FBIO, and DOMH

Should you buy Sangamo Therapeutics stock or one of its competitors? MarketBeat compares Sangamo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sangamo Therapeutics include SAB Biotherapeutics (SABS), Codexis (CDXS), Agenus (AGEN), Fortress Biotech (FBIO), and Dominari (DOMH). These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

SAB Biotherapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	212.00	$13.27M	-$2.11	N/A
Sangamo Therapeutics	$39.55M	1.78	-$122.93M	-$0.38	N/A

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Sangamo Therapeutics. SAB Biotherapeutics' average media sentiment score of 0.96 beat Sangamo Therapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
SAB Biotherapeutics	Positive
Sangamo Therapeutics	Neutral

SAB Biotherapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. SAB Biotherapeutics' return on equity of -0.29% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

SAB Biotherapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

SAB Biotherapeutics presently has a consensus target price of $11.63, suggesting a potential upside of 217.62%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 3,135.29%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

SAB Biotherapeutics beats Sangamo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Codexis?

Codexis (NASDAQ:CDXS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Codexis presently has a consensus target price of $5.00, suggesting a potential upside of 101.61%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 3,135.29%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Codexis has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Codexis has higher revenue and earnings than Sangamo Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.20	-$43.97M	-$0.37	N/A
Sangamo Therapeutics	$39.55M	1.78	-$122.93M	-$0.38	N/A

78.5% of Codexis shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Codexis had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 1 mentions for Codexis and 0 mentions for Sangamo Therapeutics. Codexis' average media sentiment score of 0.43 beat Sangamo Therapeutics' score of 0.00 indicating that Codexis is being referred to more favorably in the media.

Company	Overall Sentiment
Codexis	Neutral
Sangamo Therapeutics	Neutral

Codexis has a net margin of -40.97% compared to Sangamo Therapeutics' net margin of -310.81%. Codexis' return on equity of -68.09% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

Codexis beats Sangamo Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Agenus?

Agenus (NASDAQ:AGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Agenus currently has a consensus target price of $23.00, indicating a potential upside of 671.81%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 3,135.29%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Agenus had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Agenus and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Agenus' score of -0.15 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Agenus	Neutral
Sangamo Therapeutics	Neutral

Agenus has a net margin of 50.49% compared to Sangamo Therapeutics' net margin of -310.81%. Agenus' return on equity of -31.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

61.5% of Agenus shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Agenus has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.09	$120K	$1.59	1.87
Sangamo Therapeutics	$39.55M	1.78	-$122.93M	-$0.38	N/A

Agenus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Summary

Agenus beats Sangamo Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Fortress Biotech?

Sangamo Therapeutics (NASDAQ:SGMO) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	1.78	-$122.93M	-$0.38	N/A
Fortress Biotech	$66.16M	1.47	$6.82M	$3.17	0.92

In the previous week, Fortress Biotech's average media sentiment score of 1.87 beat Sangamo Therapeutics' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Fortress Biotech	Very Positive

Sangamo Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 3,135.29%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 480.20%. Given Sangamo Therapeutics' higher probable upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has a net margin of 193.12% compared to Sangamo Therapeutics' net margin of -310.81%. Fortress Biotech's return on equity of 109.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Fortress Biotech	193.12%	109.66%	45.56%

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fortress Biotech beats Sangamo Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Dominari?

Sangamo Therapeutics (NASDAQ:SGMO) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Dominari	-31.37%	-206.20%	-155.26%

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	1.78	-$122.93M	-$0.38	N/A
Dominari	$123.10M	0.59	-$22.43M	-$4.03	N/A

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

In the previous week, Dominari had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 1 mentions for Dominari and 0 mentions for Sangamo Therapeutics. Dominari's average media sentiment score of 0.72 beat Sangamo Therapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Dominari	Positive

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 3,135.29%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sangamo Therapeutics beats Dominari on 9 of the 16 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.43M	$3.37B	$6.45B	$12.20B
Dividend Yield	N/A	2.25%	2.66%	5.66%
P/E Ratio	-0.39	19.64	23.92	24.34
Price / Sales	1.78	306.08	517.93	135.34
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-4.25	8.00	10.50	6.70
Net Income	-$122.93M	$23.89M	$3.56B	$337.21M
7 Day Performance	13.26%	0.88%	0.19%	1.78%
1 Month Performance	25.93%	-0.39%	1.53%	3.65%
1 Year Performance	-66.00%	43.72%	24.25%	28.22%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	1.1591 of 5 stars	$0.17 +3.0%	$5.50 +3,135.3%	-66.4%	$70.43M	$39.55M	N/A	480	Gap Up
SABS SAB Biotherapeutics	3.6804 of 5 stars	$3.40 +0.6%	$11.00 +223.5%	+128.1%	$258.45M	$1.32M	N/A	140	Analyst Forecast
CDXS Codexis	2.0475 of 5 stars	$2.61 +2.0%	$5.00 +91.6%	+11.7%	$232.70M	$70.39M	N/A	250
AGEN Agenus	2.1885 of 5 stars	$3.14 -2.8%	$23.00 +632.5%	-30.9%	$134.51M	$114.20M	1.97	440
FBIO Fortress Biotech	4.0004 of 5 stars	$2.85 +7.5%	$17.00 +496.5%	+54.6%	$88.03M	$63.26M	0.90	170	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. SABS, CDXS, AGEN, FBIO, and DOMH

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

Summary

How does Sangamo Therapeutics compare to Codexis?

Summary

How does Sangamo Therapeutics compare to Agenus?

Summary

How does Sangamo Therapeutics compare to Fortress Biotech?

Summary

How does Sangamo Therapeutics compare to Dominari?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. SABS, CDXS, AGEN, FBIO, and DOMH

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

Which has higher valuation and earnings, SABS or SGMO?

Does the media favor SABS or SGMO?

Is SABS or SGMO more profitable?

Which has more risk & volatility, SABS or SGMO?

Do analysts recommend SABS or SGMO?

Do institutionals and insiders hold more shares of SABS or SGMO?

Summary

How does Sangamo Therapeutics compare to Codexis?

Do analysts recommend CDXS or SGMO?

Which has more risk & volatility, CDXS or SGMO?

Which has higher valuation and earnings, CDXS or SGMO?

Do institutionals and insiders hold more shares of CDXS or SGMO?

Does the media favor CDXS or SGMO?

Is CDXS or SGMO more profitable?

Summary

How does Sangamo Therapeutics compare to Agenus?

Do analysts recommend AGEN or SGMO?

Does the media prefer AGEN or SGMO?

Is AGEN or SGMO more profitable?

Do insiders & institutionals believe in AGEN or SGMO?

Which has higher earnings and valuation, AGEN or SGMO?

Which has more risk and volatility, AGEN or SGMO?

Summary

How does Sangamo Therapeutics compare to Fortress Biotech?

Which has more risk & volatility, SGMO or FBIO?

Which has higher valuation & earnings, SGMO or FBIO?

Does the media refer more to SGMO or FBIO?

Do analysts recommend SGMO or FBIO?

Is SGMO or FBIO more profitable?

Do institutionals & insiders have more ownership in SGMO or FBIO?

Summary

How does Sangamo Therapeutics compare to Dominari?

Is SGMO or DOMH more profitable?

Do institutionals and insiders hold more shares of SGMO or DOMH?

Which has stronger valuation & earnings, SGMO or DOMH?

Which has more risk and volatility, SGMO or DOMH?

Does the media refer more to SGMO or DOMH?

Do analysts recommend SGMO or DOMH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools